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ABSTRACT
Adult patients who present with papilloedema
and symptoms of raised intracranial pressure
need urgent multidisciplinary assessment
including neuroimaging, to exclude life-
threatening causes. Where there is no apparent
underlying cause for the raised intracranial
pressure, patients are considered to have
idiopathic intracranial hypertension (IIH). The
incidence of IIH is increasing in line with the
global epidemic of obesity. There are
controversial issues in its diagnosis and
management. This paper gives a practical
approach to assessing patients with
papilloedema, its investigation and the
subsequent management of patients with IIH.
INTRODUCTION
Idiopathic intracranial hypertension (IIH)
is becoming increasingly prevalent in line
with the global epidemic of obesity.1 In
the UK, 22.7% of people are obese
(Body Mass Index >30 kg/m2), while
obesity throughout the world has
doubled since 1980. Clinicians’ attitudes
to IIH vary: in our experience, only a
minority of patients are at high risk of
rapid visual loss.2 The previously quoted
figure of 25% developing severe perman-
ent visual loss is probably an overesti-
mate.2 The reality for patients is that it is
a chronic condition characterised by sig-
nificantly disabling headaches and psy-
chological morbidity.
The nomenclature for IIH has changed
over the years: previous names being
serous meningitis, pseudotumour cerebri
or benign intracranial hypertension. The
latter became inappropriate with aware-
ness that this is not a benign condition,
given the risk of visual loss and disabling
chronic headaches. Pseudotumour cerebri
is becoming increasingly popular as a
term to encompass primary raised intra-
cranial pressure where there is no identi-
fiable cause—which we term IIH—and
secondary causes of raised pressure.3
The diagnostic criteria of IIH are well
known and have evolved since Dandy’s
initial description in 19374; they include
a CSF opening pressure of ≥25 cm H2O
(box 1).3 However, these criteria recom-
mend imaging only to exclude a venous
sinus thrombosis in patients without the
typical IIH phenotype (obesity and
female sex). We feel, however, that it is
essential to exclude venous sinus throm-
bosis (using MRI or CTwith venography)
in all patients presenting with pseudotu-
mour cerebri, since being female and
obese does not preclude the diagnosis of
venous sinus thrombosis. The diagnosis
can be difficult and the consequences of
error can lead either to the neglect of a
serious treatable cause of raised intracra-
nial pressure, blindness or inappropriate
treatment of patients who do not have
IIH. Although there is insufficient litera-
ture to generate an evidence-based man-
agement strategy for IIH,5 experienced
clinicians can manage it well.
AN APPROACH TO PAPILLOEDEMA
Patients generally present to the emer-
gency department after an optometrist or
family doctor detects papilloedema. They
may or may not have other symptoms.
Because papilloedema indicates poten-
tially serious underlying disease, the
purpose of the visit is to recognise and
confirm the presence of papilloedema and
arrange appropriate onward investigation.
An important issue is that, in the UK, the
most junior and inexperienced doctor
often assesses the patient first to confirm
the clinical finding of papilloedema. Once
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an ophthalmologist (of any grade) labels the patient as
having papilloedema, this is rarely questioned further,
and the pathway of investigations moves forward.
Recognising papilloedema is usually straightforward
(figure 1) but occasionally it can be very difficult to dis-
tinguish papilloedema from congenitally anomalous
discs and pseudopapilloedema (figure 2). Where there
is diagnostic difficulty, it is best to seek early assessment
by neuro-ophthalmology, or a senior ophthalmologist
with experience in differentiating swollen from appar-
ently swollen optic discs. This avoids invasive investiga-
tions in the normal patient.
Case 1—Are you sure it is papilloedema?
A 23-year-old right-handed woman was referred by
her optician to the emergency unit with longstanding
headaches and swollen optic discs. Since the age of
12 years, she had experienced frequent headaches and
recently had developed continuous tinnitus. She had
no previous medical or ocular history and currently
took no medication. On examination, her Body Mass
Index was 36 kg/m2. Her visual acuities were 6/6 bilat-
erally, aided with a small hypermetropic correction
(right eye+1.75 diopters sphere and left eye+1.25
diopters sphere). She was already dilated after seeing
the optician and the emergency doctor noted nasal disc
margin blurring. She underwent normal neuro-imaging
(MRI and MR venogram). Her lumbar puncture
opening pressure was 26 cm CSF with normal constitu-
ents. She was discharged on oral acetazolamide
250 mg four times daily with a routine outpatient
appointment for neuro-ophthalmology. Her disc
photos showed small anomalous discs, and the visual
field showed a typical clover leaf appearance, suggest-
ing difficulty producing a reliable field. (Figure 3).
CLUES FROM THE HISTORY
Headaches are common and can be highly variable
(see later). They may be of new onset or more
chronic, particularly in those with previous migraine.
Visual symptoms include blurred or double vision.
Patients can describe transient loss of vision and/or
‘greying out’ of vision: so-called ‘transient visual
obscurations’. They usually relate to postural changes;
and are usually brief, typically only seconds. Patients
may report horizontal diplopia from a false-localising
abducens nerve palsy. There may be pulsatile tinnitus
—a rhythmic ‘whooshing’ sound heard in either or
both ears synchronous with the patient’s heartbeat,
and often present only on lying down. Many patients
do not volunteer this symptom unless directly asked.
CLUES FROM THE EXAMINATION
Clinicians should examine visual function (table 1)
and extraocular movements in all cases.
Distinguishing pseudopapilloedema from papilloedema
This requires clinical experience. Pseudopapilloedema
may be due to congenitally anomalous discs, optic
nerve head drusen or a combination of the two.
Congenitally anomalous discs are small nerves that lack
a physiological cup. Optic nerve head drusen are
globular hyaline bodies, which may be calcified. They
are often seen incidentally during routine eye tests and
up to 2% of the general Caucasian population may
have them. Sometimes, they are obvious (figure 4).
However, they are difficult to see when buried, the
only clue being increased retinal vessel branching at the
optic nerve head (figure 5). Ophthalmic ultrasound
scanning (figure 6) can confirm their presence. Very
occasionally when there is still diagnostic doubt such
as, ‘are these congenitally anolamous discs swollen?’
fundus fluorescein angiography can help to determine
if there is disc leakage (figure 7).
It can be extremely difficult to distinguish pseudopa-
pilloedema from papilloedema and, where there is
uncertainty, clinicians must keep an open mind.
Inappropriately labelling pseudopapilloedema as IIH
can have significant negative implications, and we have
seen these cases complicated by morbidity from surgi-
cal shunting and the side effects of acetazolamide.
INVESTIGATION
Having identified papilloedema, it is essential to
record blood pressure to exclude malignant hyperten-
sion. Patients then need urgent neuroimaging: this has
two purposes, to identify any space-occupying lesion
and to exclude a venous sinus thrombosis. The pre-
ferred imaging method is an MR scan of the head and
orbits with intravenous contrast and MR venogram;
these should, ideally, include fat suppression
sequences, as these better define the intraorbital optic
nerves. However, if this is not readily available, a CT
head scan with a CT venogram will exclude most
Box 1 Diagnostic criteria for adult IIH*
▸ Papilloedema.
▸ Normal neurological examination except for cranial
nerve abnormalities.
▸ Neuroimaging: Normal brain parenchyma without
hydrocephalus, mass or structural lesion and no
abnormal meningeal enhancement or venous sinus
thrombosis on MRI and MR venography; if MRI is
unavailable or contraindicated, contrast-enhanced CT
may be used.
▸ Normal CSF composition.
▸ Elevated CSF opening pressure (≥25 cmH2O) in a
properly performed lumbar puncture.
▸ A diagnosis of IIH is definite in patients fulfilling A–E;
the diagnosis is probable if A–D are met but the CSF
pressure is lower than specified.
*Adapted from the 2013 revised diagnostic criteria for
IIH.3
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space-occupying lesions, cerebral venous sinus throm-
bosis and Chiari malformation. There are several pos-
sible radiological signs of IIH, although none is
pathognomonic (figure 8). There may be an empty
sella, a partially empty sella, decreased pituitary
height or transverse sinus narrowing. In the orbits, the
optic nerve sheath complex may be enlarged, the pos-
terior globe flattened and occasionally the optic nerve
head protruded.4
After excluding a structural intracranial lesion,
patients require a lumbar puncture, performed with the
patient in the lateral decubitus position. The opening
pressure is important, so every effort should be made to
ensure all equipment is at hand; this includes having
more than one packet of manometer tubes to avoid
being unable to measure a pressure >40 cm CSF. The
patient must be comfortable, as Valsalva, talking, crying
and flexed legs compressing an obese abdomen, may
artificially raise the pressure reading. We suggest slightly
straightening the patient’s legs at the hips to avoid com-
pressing the intra-abdominal cavity. The column of CSF
in the manometer needs sufficient time to settle—there
should be small oscillations with breathing—before
recording the reading. Our review on a practical
Figure 1 Single colour fundus photographs of patients with disc swelling secondary to raised intracranial pressure (papilloedema). (A)
Mild papilloedema with burring and elevation of nasal disc margin (arrow). (B) Moderate papilloedema with obscuration of vessels by
oedematous nerve fibre layer. (C, D, E) Severe papilloedema with cotton wool spots, nerve fibre layer haemorrhage (arrows C and D)
and venous engorgement and tortuosity (arrow E). (F) Papilloedema with secondary optic atrophy. Note, as atrophy progresses, fewer
nerve fibres can swell.
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approach to lumbar puncture has more tips.5 Despite
optimising the conditions for lumbar puncture, it is still
a one-off reading. CSF pressure varies diurnally, so a
snapshot recording is not the whole story. It is, however,
useful retrospectively to ask the patient if their symp-
toms (obscurations, headache, etc) improved for a few
days after the lumbar puncture. Confirming a temporary
improvement supports there being raised intracranial
pressure. If the lumbar puncture is technically challen-
ging, fluoroscopic or ultrasound guidance may help. A
CSF sample should be sent for microscopy, protein and
glucose (and sometimes for xanthochromia and culture
to identify secondary causes of raised intracranial pres-
sure, such as CSF hypercellularity, eg, subarachnoid
haemorrhage and meningitis). Patients should also have
blood taken to exclude anaemia,6 to check serum
calcium, plasma glucose and renal function.
There is some debate about the limits of normal
lumbar CSF opening pressure. Whiteley et al’s clinical
study found the normal range for lumbar CSF opening
pressure was 10–25 cm CSF (95% reference interval);
but some normal subjects had opening pressures of up
to 28 cm CSF.7 Furthermore, there is only a weak, non-
significant relationship between Body Mass Index and
lumbar puncture opening pressure.7 In our experience,
a common mistake is putting too much emphasis on a
single reading, as normal people may have artificially
high or low CSF pressures. When the clinical findings
are out of keeping with the opening pressure, the pres-
sure should be questioned and, in some cases, the
lumbar puncture repeated. Occasionally, a CSF infu-
sion study can help. However, we would recommend
that all patients being evaluated for IIH whose lumbar
pressure is ≥25 cm CSF should see an experienced
neurologist or ophthalmologist to weigh up the evi-
dence towards a diagnosis of IIH.
Children with IIH often present differently to
adults, although this is beyond the scope of this
article. In other atypical cases, such as non-obese
women or men, where there is no underlying systemic
cause for raised intracranial pressure (see differential
diagnosis), we suggest extracranial imaging to exclude
pathology, such as internal jugular vein obstruction.
DIFFERENTIAL DIAGNOSIS
When there is papilloedema with symptoms and signs
of raised intracranial pressure, it is important to
obtain a thorough past history and system screen to
Figure 2 Single colour fundus photographs of pseudopapilloedema in patients initially thought to have IIH. (A) Elevated, lumpy disc
with anomalous vascular pattern including trifurcation of central retinal artery (arrow) seen in optic nerve drusen. (B) Small disc height
(arrow) leads to a crowded appearance of the optic nerve without a physiological cup. (C and D) High magnification photographs of
right and left eyes of a patient with anomalous discs which show the indistinct nasal disc margin (arrow C) and absent physiological
cup (arrow D).
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identify treatable causes (box 2). Polycystic ovarian
syndrome has a comorbid association with IIH, but
current evidence suggests that it does not raise intra-
cranial pressure.8
A comprehensive drug history is essential (table 2).
Tetracyclines, nitrofurantoin and excessive vitamin A
intake frequently appear in case reports as raising
intracranial pressure, and their withdrawal often
resolves the problem. It is possible that the previous
use of high-dose oestrogen oral contraceptives may
also contribute. This has been difficult to investigate
as many cases are women of childbearing age, and
therefore there is a high incidence of the use of these
medications in this age/sex group. If there is a strong
temporal relationship between the oral contraceptive
pill use and the diagnosis of IIH we may suggest stop-
ping it. There is no evidence base here, but our prac-
tice is to suggest switching to a progesterone pill or
barrier method. This requires careful management to
avoid unplanned pregnancies. For patients with IIH
wanting to start the oral contraceptive pill, we typic-
ally arrange more frequent review after starting it, but
rarely note any problems.
Figure 3 Case one: (A and B) Right and left colour fundus photographs of the optic nerve head showing small crowded discs with
anomalous branching of the blood vessels. (C and D) Left and right grey-scale plot taken from the Humphrey visual field test printout,
showing he ‘clover leaf’ pattern of an unreliable test performance.
Table 1 Mandatory visual function measurements
Visual acuity Test each eye separately for the best corrected
(with glasses) distance visual acuity, using either
Snellen’s or logMar chart.
Use a pinhole to record improvement after
correcting for refractive error
Colour vision Test each eye individually with pseudoisochromatic
plates, such as Ishihara’s plates
Pupil examination To exclude a relative afferent pupillary defect and
oculosympathetic palsy (Horner’s syndrome)
Visual field
assessment
Assess visual fields (either a Humphrey’s or
Goldmann’s), as confrontational visual fields picks
up only gross defects
Dilated fundus
examination
Document optic nerve head AND macular findings.
This is important to exclude intraocular
inflammation causing bilateral disc oedema. Ideally
assess using a slit lamp.
Figure 4 Surface and buried optic nerve head drusen.
The disc is elevated and lumpy with visible yellowish deposits
(drusen) within the optic nerve head. Note the absence of the
physiological cup and anomalous vascular branching (arrow).
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MONITORING IN IIH
Routine clinical observation involves monitoring of
the visual function (table 1). Clinicians often ask what
is the best technique for monitoring visual fields: at
our unit, we use Humphrey visual fields as in Case 1,
and Goldmann visual fields as in case 2. Patients need
serial visual fields, and it is best to use the same form
of perimetry each time. We prefer Humphrey in those
patients capable of concentrating and completing the
tests as it is sensitive and reproducible. However, it is
important not to interpret a field based entirely on
the grey-scale plot, and to consider the reliability
indices (fixation losses, false positives and false nega-
tives). A patient with inattention, or poor compliance
with the test, may show a dramatic visual field deficit,
as in Case 1, often with a high false-negative rate.
Goldmann visual fields can be performed on
manual and automated machines. Typically, the per-
iphery is plotted using a kinetic (moving) target, and
the central visual field is tested statically. Manual per-
imetry using a Haag–Streit Goldmann perimeter
requires a skilled operator; it is useful for neuro
patients with serious visual loss, or those needing
significant supervision and encouragement to produce
a reliable visual field. We find that non-organic visual
loss is common in IIH, and so it is important to have
a skilled operator who has time allowed for the
patient.
Direct imaging of the optic nerve head is also useful
in objectively assessing and longitudinally monitoring
papilloedema and where there is fluid tracking to the
macula. Colour fundus photography is an excellent
way to record the fundal findings. Optical coherence
tomography is becoming a superior technique, as it
can measure swelling at the optic nerve head and the
macula. Optical coherence tomography is very quick
with the spectral (or Fourier) domain scan rate of at
least 20 000 axial scans per second. It is non-invasive
and provides high-resolution images with an axial
resolution of 3–5 μm. Ultrasonographic B-scanning
can also measure the optic disc height and the pres-
ence of excessive fluid within the optic nerve sheath
(a surrogate marker of papilloedema).
MANAGEMENT
Disease evolution and outcomes in IIH are poorly
characterised and are currently being evaluated in the
National IIH:LIFE study (centres interested in partici-
pating should contact the author, AS). We have noted
the following patient types:
▸ Those who rapidly lose vision at diagnosis over days to
weeks (rare but vital to identify early).
▸ Those whose disease resolves following diagnosis, over
weeks to months, occasionally after a single lumbar
puncture (rare).
▸ Those at lower risk of visual loss who develop chronic
disease with small fluctuations in disease activity, fre-
quently with weight changes (the majority).
▸ Those in disease remission and off treatment.
For most patients, the clinical priority is to monitor
vision and help the disease into remission. The head-
ache symptoms typically comprise the greatest mor-
bidity for these patients (see later). For patients in
remission (the fourth cohort) with no papilloedema
noted on visits over several years, we will aim to dis-
charge and advise annual optometrist assessments, but
return if any symptoms recur.
Management of acute visual loss in IIH
In high-risk patients with impending visual loss, some
form of CSF divergence can be sight-saving. If the sur-
gical procedure is likely to be delayed for 24–48 h, it
is possible to insert a lumbar drain at the time of the
lumbar puncture. The type of procedure depends on
the local expertise and the neurosurgeon’s preference.
The clear immediate benefit is preserved vision, and
sometimes reversal of visual loss (Case 2). Options
include a lumboperitoneal shunt, where a catheter is
inserted into the subarachnoid space at the lumbar
spine between two vertebrae and fed around the
oblique muscles under the skin into the peritoneum.
Figure 5 Colour fundus photograph of buried drusen.
Elevated disc with absent physiological cup (arrow).
Figure 6 B-scan ultrasound of the right optic nerve, showing
optic nerve head drusen. Ovoid echogenic foci in optic nerve
(arrow).
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Figure 7 Fundus fluorescein angiography of the left eye with papilloedema. A rapid series of fundus photographs follow the
intravenous injection of a fluorescent contrast agent. In true disc swelling, the frames (A–E) show progressively increased intensity and
area of fluorescence at the disc. This shows fluorescein leakage from the oedematous disc.
Figure 8 (A) MRI T1-weighted sagittal image showing a partially empty sella. (B) MRI T2-weighted coronal imaging showing
increased fluid in the optic nerve sheath complex bilaterally. (C) MRI T1-weighted axial image showing flattening of the posterior
globes, and dilated optic nerve sheaths in patient with raised intracranial pressure.
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We tend to avoid this in patients with low-lying cere-
bellar tonsils, as there is an increased risk of tonsillar
descent following the shunt, with subsequent disabling
cough headaches. A ventriculoperitoneal shunt diverts
CSF from the lateral ventricle to the peritoneum. Less
commonly, a ventriculoatrial shunt can divert CSF
from the lateral ventricle to the atrium of the heart,
or a ventriculopleural shunt diverts it to the pleural
cavity. The surgical risks include shunt malfunction,
infection and over-drainage. Over half the patients
need shunt revision, and one-third need multiple revi-
sions.9 We use shunting as a temporary measure to
save vision in those at risk of impeding visual loss.
While the shunt is working, we advise weight reduc-
tion to put their disease into remission. Additionally,
we almost never recommend shunting exclusively to
treat headache, as this continues in most patients post-
operatively (68% at 6 months and 79% at 2 years).9
Also, postoperative low-pressure headache occurs in
28%.9 We recommend using shunts with a valve
system and CSF reservoir to reduce the morbidity
from over-drainage and under-drainage.
Optic nerve sheath fenestration is an alternative for
protecting the vision; however, it has little effect on
the overall intracranial pressure and can lead to visual
loss in inexperienced hands.
Case 2
A 24-year-old woman presented with increasing blur-
ring and ‘greying’ out of her left eye vision, particularly
when bending over. She had a 3-week history of new
onset headache, present on waking and of increasing
severity. She reported a loud ‘whooshing’ noise in her
left ear in the previous week. She had been previously
well and her Body Mass Index was 34 kg/m2. Visual
acuity was 6/18 (right) and 1/60 (left). There was
reduced colour vision in the left, with a relative affer-
ent pupillary defect. There was extensive visual field
loss in the left eye (figure 9). Her MR scan of brain
and MR cerebral venogram were normal. The lumbar
puncture opening pressure was 90 cm CSF, with
normal constituents. She underwent a lumboperitoneal
shunt within 24 hours of presentation. Her vision
returned to 6/9 in both eyes, and her immediate post-
operative fields were markedly improved.
Conservative management
Weight loss
Some patients volunteer recent weight gain before pres-
entation, others do not, but weight loss is currently the
only proven disease-modifying treatment for all over-
weight patients.10 11 Our recent prospective study high-
lighted that a 15% reduction of body weight, using a
low calorie meal replacement liquid diet for 3 months,
significantly reduced intracranial pressure, papilloedema
and headaches.10 However, strategies to achieve long-
term significant weight loss are notoriously difficult
with typically as little as 2–4 kg of weight loss main-
tained at 2 years irrespective of the diet followed.12
Many case reports describe the benefits of bariatric
surgery in IIH.13 We are currently recruiting to a rando-
mised controlled trial comparing efficacy and cost-
effectiveness of the most effective community weight
loss programme14 versus bariatric surgery.
Pharmacological management
Carbonic anhydrase inhibitors, such as acetazolamide,
can provide symptomatic relief of raised intracranial
pressure, although there is no evidence to support
their benefit. Additionally, in the only randomised
controlled trial looking at acetazolamide, over half the
patients in the acetazolamide arm stopped treatment
due to side effects.15 This aligns with our clinical
experience that many cannot tolerate it. For these
reasons, we manage many of our patients with active
IIH without acetazolamide. The maximum dose is up
to 2 g/daily; in our experience, up to 1 g daily is
adequate, depending on body weight. If we do pre-
scribe acetazolamide, we use the modified release
preparation to reduce side effects.
Managing venous stenoses
Many patients with pseudotumour cerebri have venous
sinus stenosis (narrowing), particularly of the transverse
sinuses, reflecting elevated intracranial pressure.16
Box 2 Secondary causes of raised intracranial pressure
for exclusion to diagnose IIH
▸ Secondary causes of raised intracranial pressure.
▸ Venous sinus thrombosis.
▸ Anaemia.
▸ Obstructive sleep apnoea.
▸ Drug-related.
▸ CSF hyperproteinaemia/hypercellularity, for example,
spinal cord tumour/meningitis/Guillain–Barré syn-
drome/subarachnoid haemorrhage.
▸ Renal failure.
▸ Endocrine diseases, for example, Addison’s/
Cushing’s/hypothyroidism.
Table 2 Drugs associated with pseudotumour cerebri
Tetracycline/minocycline/
doxycycline
Corticosteroids
(and withdrawal)
Nitrofurantoin Beclometasone
Sulphonamides, for example,
trimethoprim
Cimetidine
Nalidixic acid Lithium
Vitamin A excess and retinoids Tamoxifen
Depo Provera Ciclosporin
Combined oral contraceptive pill Non-steroidal anti-inflammatory
drugs
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Several research centres are now evaluating the thera-
peutic potential of stenting the transverse sinus in
IIH.17–20 There is growing consensus that the stents do
not treat the underlying cause of IIH. Reducing intracra-
nial pressure by lumbar puncture can resolve the sten-
oses.21 Stenting the stenoses may, however, improve IIH
by increasing CSF drainage at the arachnoid granula-
tions, thereby lowering intracranial pressure and
improving the signs and symptoms of IIH.17–20 Serious
complication of the procedure (venous sinus perfor-
ation, stent migration, in-stent thrombosis, subdural
haemorrhage and the development of recurrent stenoses
immediately proximal to the stent) suggest the need for
caution with this approach.17–19 We need larger long-
term randomised clinical trials to evaluate this treatment
before it can become routine clinical practice.22
Managing the headache
The priority for patients with chronic IIH is usually
the control of disabling headaches. IIH headache
characteristics are very variable. Many do not have
the classical features of IIH headache described by the
International Headache Society23 (progressive, daily,
diffuse, non-pulsatile headache with aggravation by
coughing or straining).24 We note that pressure fea-
tures, such as aggravation with Valsalva or cough and
severity worse in the morning (having been recumbent
in the night) often do not occur, particularly as the
condition becomes more chronic. The headaches typ-
ically alter during the course of the disease. In
keeping with the literature, we find that headaches are
often multifactorial, either due to raised intracranial
pressure, low pressure, medication overuse headache,
migraine or a combination of these.25–27 Migrainous
features are particularly common (>70% of
patients).28 Our practice, particularly in those in
whom headache is the principal complaint, is to evalu-
ate the headache phenotype fully and to focus treat-
ment towards the principal headache type. Those with
chronic burnt-out disease—typically with stable vision
and no or minimal papilloedema—often have the
greatest headache disability. There is little evidence
base to guide headache management in IIH. We look
for, educate about, and treat the frequent situation of
medication overuse in IIH. We successfully use topira-
mate—a migraine prophylactic agent with weak car-
bonic anhydrase inhibitor activity and an appetite
suppressant (in about 10%),29—to treat headache in
IIH. Amitriptyline also helps to reduce the impact of
migrainous headaches. A headache diary is very
useful, not just to quantify the headache load, but also
for the patient.
Figure 9 Case 2—Urgent CSF divergence surgery restored visual function. (A, B) Goldmann visual fields before and (C, D) after
lumbar peritoneal shunt (left and right). (A) The left eye has an extensive visual field deficit and visual acuity of 1/60, the field is
plotted (in green) only to the largest, brightest target called V4e (arrow). The patient was not able to perceive the smaller/ dimmer
targets plotted in red, blue and black in figures 9B-D. (B) The right eye has an enlarged blind spot and reduced sensitivity of the
visual field and visual acuity 6/18. (C and D) Left and right eye following the shunt show improved visual field and vision to 6/9 in
both eyes.
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Managing IIH without papilloedema. These patients
typically have chronic headaches, and in some their
phenotype (obesity and female sex) or symptoms of pul-
satile tinnitus prompt a lumbar puncture with pressure
measurement. It is not clear if IIH without papilloedema
is a distinct pathological entity30 31 and there is debate
as to whether these patients represent just chronic daily
headache with a coincidentally elevated intracranial
pressure.32 Pressures in these patients tend to be signifi-
cantly lower than in typical IIH.33 Friedman et al has
suggested that the diagnosis of IIH without papilloe-
dema should only be made in those with a unilateral or
bilateral sixth nerve palsy that also fulfil the criteria B-E
in box 1. Alternatively, criteria B-E in association with at
least three imaging findings suggesting raised intracra-
nial pressure (empty sella, flattened posterior aspect of
the globe, distended perioptic subarachnoid space±a
tortuous optic nerve and transverse sinus stenosis).3
These criteria may be too stringent and lead to the
under-identification of cases. Sixth nerve palsies are
uncommon, even in cases with frank papilloedema. As
these patients do not have (and do not seem to develop)
papilloedema, they do not tend to develop visual loss,
although they may develop functional visual loss.33
Management focuses on treating the headache, and we
use prophylactic and abortive agents appropriate for the
headache phenotype.
Managing IIH in pregnancy
As IIH is common in women of childbearing age,
there will inevitably be patients diagnosed with IIH
who become pregnant. If the patient takes acetazola-
mide, we advise her to stop this on becoming preg-
nant, to minimise the risk of toxicity, particularly in
the first trimester. However, in a series of 50 patients
treated with acetazolamide during the first trimester,
there were no reported adverse outcomes for the
pregnancy or the baby.34 We therefore occasionally
consider using acetazolamide, particularly after the
first trimester, following an informed discussion of
the potential risks and benefits.35 During pregnancy,
we increase observations and begin communication
with the obstetric team; we advise that the mother’s
birth plans are not changed simply due to their diag-
nosis of IIH. We recommend specialist dietary advice
to guide on appropriate weight gain during pregnancy
(eg, the Maternal Lighten Up program). The Institute
of Medicine recommended 5–9 kg weight gain during
the pregnancy (0.22 kg/week in the second and third
trimester) in those with a starting Body Mass Index of
≥30 kg/m2.36 For the great majority, the IIH remains
stable and they can have a normal vaginal delivery.
Very occasionally, when there is compromised optic
nerve function, we advise against a prolonged second
stage of labour. Epidural and spinal anaesthetic during
labour (even with a shunt in situ) can still go ahead.37
A few patients present with IIH for the first time
during the first trimester. If they have visual
compromise they may require temporising serial
lumbar punctures, until they can undergo CSF diver-
sion during their second trimester.
In the postpartum period, acetazolamide is probably
safe for a breastfeeding baby. Only 0.06% of the dose
of acetazolamide given to the mother is ingested by
the child (less than 0.7% of the dose/kg body weight
received by the mother); such a low dose is unlikely
to harm the baby.38
CONCLUSIONS
Patients presenting with papilloedema need careful
evaluation and timely investigation. This is required to
exclude all other causes of swollen optic nerves and
raised intracranial pressure: IIH is a diagnosis of exclu-
sion. Acute management depends on the immediate
risk to vision. For most patients, this is a chronic condi-
tion associated with significant disability from head-
ache. Disease-modifying therapy is weight loss. CSF
shunting should be considered temporary. IIH requires
a multidisciplinary approach involving ophthalmolo-
gists, neurologists and neurosurgeons. These patients
are best managed in centres with expertise in IIH.
Practice points
▸ Distinguishing papilloedema from pseudopapilloe-
dema is not always straightforward, and may require
a senior ophthalmology opinion.
▸ Pseudotumour cerebri describes raised intracranial
pressure and papilloedema in the absence of a space-
occupying lesion and can be caused by several condi-
tions (box 2). Idiopathic intracranial hypertension is a
diagnosis of exclusion where NO cause can be found.
▸ A single lumbar puncture opening pressure reading
can be misleading. Where the opening pressure is
out of keeping with the clinical picture, the clinician
should review the whole case.
▸ Monitoring of visual fields can be problematic in
many patients who have functional overlay.
▸ Treat the patient. High-risk patients lose vision rapidly.
Headaches may be multifactorial, and require special-
ist evaluation and treatment to reduce disability.
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